

## **REMARKS/ARGUMENTS**

Claims 1-14 and 48-49 are presently pending. Claim 1 is amended herein.

### **Claim Amendments**

Claim 1 is amended to clarify that “pretargeting an enzyme to a mammalian site” comprises, “(i) administering a bispecific antibody or fragment, wherein one arm of the bispecific antibody is targeted against a target site antigen and a second arm is targeted against a low molecular weight hapten that is conjugated to said enzyme,” and “(ii) administering a low molecular weight hapten that is conjugated to said enzyme.” Support for the amendment may be found in the published Specification (No. 20020114808) at least at Paragraph [0019] and Examples 3-7.

### **Claim Rejections – 35 U.S.C. § 112**

Claims 1-14 and 48-49 are rejected under 35 U.S.C. 112, 2<sup>nd</sup> paragraph as incomplete for omitting essential steps. The Action asserts that the omitted steps are: (1) administration of a bispecific antibody or antibody thereof [*sic*], wherein one arm of the bispecific antibody is targeted against a target site antigen and a second arm is targeted against a low molecular weight hapten that is conjugated to said enzyme; and (2) administration of a low molecular weight hapten that is conjugated to an enzyme.”

Claim 1 is amended herein to clarify that “pretargeting an enzyme to a mammalian site” comprises, “(i) administering a bispecific antibody or fragment, wherein one arm of the bispecific antibody is targeted against a target site antigen and a second arm is targeted against a low molecular weight hapten that is conjugated to said enzyme,” and “(ii) administering a low molecular weight hapten that is conjugated to said enzyme.”

Applicants submit that the amendment overcomes the rejection. Reconsideration and withdrawal of the rejection is respectfully requested.

### **Double Patenting**

Claims 1, 4-5 and 11 are rejected on the ground of nonstatutory obviousness-type double patenting over claims 1, 4-5, 16-18 and 24-25 of U.S. Patent No. 6,962,702.


Submitted herewith is a terminal disclaimer over U.S. Patent No. 6,962,702.

**Conclusion**

For the reasons stated above, Applicants submit that the amended claims are in condition for allowance and request withdrawal of the rejections.

Respectfully submitted,

Dated: April 16, 2007

  
\_\_\_\_\_  
Richard A. Nakashima  
Reg. No. 42,023